Tolicizumab: a new option for refractory idiopathic recurrent pericarditis: a case report
Interleukin-6 is a key cytokine in the pathogenesis of pericarditis, acting synergistically with IL-1 to drive inflammation and acute phase responses. In our patient, blockade of IL-6 with tocilizumab led to the complete resolution of inflammation, suggesting a possible new therapeutic option for refractory cases. This result highlights the potential of IL-6 inhibition as an alternative strategy, when IL-1 blockers are contraindicated or ineffective.
Authors
- Francesco Venturelli (ORCID: https://orcid.org/0000-0002-7133-3713)
- Roberta Sappa (ORCID: https://orcid.org/0000-0003-0015-0490)
- Filippo Quinzani
- Massimo Imazio (ORCID: https://orcid.org/0000-0002-5722-0245)
- Valentino Collini (ORCID: https://orcid.org/0000-0003-0008-4630)
Institutions
- University of Udine (IT)
- Ospedale Santa Maria della Misericordia di Udine (IT)
- Azienda Sanitaria Universitaria Integrata di Trieste (IT)
- Istituti Ospitalieri di Cremona (IT)
- Misericordia University (US)
Publication Details
- Journal
- European Heart Journal - Case Reports
- Published
- 2025-10-23
- DOI
- https://doi.org/10.1093/ehjcr/ytaf535
- Citations
- 1
- Primary Topic
- Pericarditis and Cardiac Tamponade
- Type
- article
- Field-Weighted Citation Impact
- 1.39